알츠하이머 치매 약물치료의 현황과 미래

• 영문명: Past and Future of Drug Treatments for Alzheimer s Disease
• 발행기관: 대한신경정신의학회
• 저자명: 김성윤
• 간행물 정보: 『신경정신의학』제57권 제1호, 30~42쪽, 전체 13쪽
• 주제분류: 의약학 > 정신과학
• 파일형태: PDF
• 발행일자: 2018.02.28

영문 초록

This study reviews evidence for the use of acetyl-choline esterase inhibitors (AChEIs) in treating Alzheimer s patients for the past decades. Even though large number of clinical trials have been conducted to prove the efficacy of these drugs in various clinical situations, questions remain to be answered due to the use of heterogeneous subject population, trial designs, and measurement tools in these studies. Many drugs with unproven clinical benefits, including vitamins, ginko biloba extracts, anti-inflammatory agents, estrogen hormone, and statins, are commonly prescribed in real-world settings for dementia patients. Despite the lack of clinical benefits statistically proven by clinical trials or meta-analyses, anecdotal dramatic improvements in some patients may foster such practices. A further look into why some patients benefit from these medications, while other don t, may shed light on future individually tailored medicine for dementia patients. This study provides a brief review of currently existing immuno-therapeutics in the hope that we can learn from the failures of the amyloid-based active and passive immunization. Issues that we need to address for the successful development of new anti-AD drugs include : 1) the brain pathology precedes clinical symptoms by several decades, 2) we need biological markers that reliably reflect cognitive or functional impairment of AD patients, and 3) we need more detailed and plausible explanations for our brain immune responses and neurodegenerative changes.

목차

서론

알츠하이머 치매의 인지증상 개선을 위한 약물

임상시험 근거가 미약하나 현실적으로 사용되고 있는 약물들

임상시험이 진행 중인 실험적 약물들

결론

Notes

References

키워드

알츠하이머 치매 약물치료 아밀로이드 타우 콜린 분해효소 억제제